Kidus Profile

Bronze Writer Badge


Location: Ethiopia

Gender: M

Member Since: May 2021

Last online: May 2021

Open for read requests: Yes

Subscribe to Kidus's portfolio via RSS

Featured by author

Profile Information

Consistently, seven individuals some place on Earth experience one of humanity's most productive executioners: a shape-moving parasite conveyed in the salivation of female mosquitoes that can dodge our invulnerable frameworks and live in our livers and platelets. Like clockwork, the parasite asserts another casualty younger than five years of age—and brings another round of tragedy and misfortune. This dreary cycle plays out very hour, consistently, consistently, consistently. 

For over 10 years, Halidou Tinto has faced this executioner. Tinto, a disease transmission specialist, master on intestinal sickness, and a territorial overseer of Burkina Faso's Institute of Research in Health Sciences, serves the locale of Nanoro, somewhere in the range of 50 miles northwest of the capital Ouagadougou. With the appearance of the African rainstorm each late spring, jungle fever cases spike in Nanoro and networks the nation over. Burkina Faso, a nation of 20 million, records around 11 million jungle fever cases a year—just as 4,000 passings. 

Yet, following quite a while of talking with neighborhood families about partaking in another intestinal sickness immunization preliminary, long periods of involvement in running clinical preliminaries around there, and many years of worldwide exploration behind him, Tinto's site in Nanoro is home to something different: trust. 

In an examination distributed in The Lancet on Wednesday, a worldwide group has shared promising new information on a likely antibody. The stage two preliminary, in light of 450 kids in Nanoro, assessed the R21 jungle fever immunization applicant, which has been a work in progress in the United Kingdom for over 10 years. Scientists tracked down that after kids got three shots in an eight-week time frame and a supporter a year later, the R21 antibody was 77% powerful at halting intestinal sickness, when looked at against a control rabies immunization, instead of a standard fake treatment. 

R21 is the primary immunization possibility for jungle fever to pass the 75% boundary, an objective the World Health Organization (WHO) first set in 2013. On the off chance that borne out in greater preliminaries, R21 could add another integral asset to the world's jungle fever battling tool stash.


This is where you can leave a short message for the writer. All Quickees are public. To leave a private message, use the private messaging system.

If you want to write a quickee (a remark or a hint for example) on this writer's profile, please sign in.


Fans of Kidus:

Kidus is a member of: